Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

Stephen Jolles, Michael Borte, Robert Nelson, Mikhail Rojavin, Martin Bexon, John Philip Lawo, Richard L. Wasserman

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Hizentra® (20% subcutaneous immunoglobulin [SCIG]) was administered to subjects with primary immunodeficiency disease in two extension studies in the EU and US to assess long-term efficacy and tolerability. Subjects (aged 4-69. years) were treated for 148. weeks in the EU (N. = 40; 5405 infusions) and 87. weeks in the US (N. = 21; 1735 infusions). Weekly doses were 116.0. mg/kg (EU) and 193.2. mg/kg (US); IgG levels were 7.97. g/L (EU) and 11.98. g/L (US). Annualized rates of serious bacterial infections were 0.05. infections/subject/year (EU) and 0.06. infections/subject/year (US). Rates of any infection were 3.33. infections/subject/year (EU) and 2.38. infections/subject/year (US). The rate of bronchopulmonary infections was higher in the EU study. No treatment-related serious AEs occurred; no subject discontinued because of treatment-related AEs. Self-administered Hizentra afforded sustained effective protection from infections and favorable tolerability during an extended treatment period of up to 3. years.

Original languageEnglish (US)
Pages (from-to)161-169
Number of pages9
JournalClinical Immunology
Volume150
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Safety
Infection
Hizentra
Bacterial Infections
Immunoglobulins
Immunoglobulin G

Keywords

  • 20% SCIG
  • Hizentra
  • Primary immunodeficiency
  • Subcutaneous immunoglobulin

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease. / Jolles, Stephen; Borte, Michael; Nelson, Robert; Rojavin, Mikhail; Bexon, Martin; Lawo, John Philip; Wasserman, Richard L.

In: Clinical Immunology, Vol. 150, No. 2, 02.2014, p. 161-169.

Research output: Contribution to journalArticle

Jolles, Stephen ; Borte, Michael ; Nelson, Robert ; Rojavin, Mikhail ; Bexon, Martin ; Lawo, John Philip ; Wasserman, Richard L. / Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease. In: Clinical Immunology. 2014 ; Vol. 150, No. 2. pp. 161-169.
@article{58a2646b3d474ad3924cb4cf188a2268,
title = "Long-term efficacy, safety, and tolerability of Hizentra{\circledR} for treatment of primary immunodeficiency disease",
abstract = "Hizentra{\circledR} (20{\%} subcutaneous immunoglobulin [SCIG]) was administered to subjects with primary immunodeficiency disease in two extension studies in the EU and US to assess long-term efficacy and tolerability. Subjects (aged 4-69. years) were treated for 148. weeks in the EU (N. = 40; 5405 infusions) and 87. weeks in the US (N. = 21; 1735 infusions). Weekly doses were 116.0. mg/kg (EU) and 193.2. mg/kg (US); IgG levels were 7.97. g/L (EU) and 11.98. g/L (US). Annualized rates of serious bacterial infections were 0.05. infections/subject/year (EU) and 0.06. infections/subject/year (US). Rates of any infection were 3.33. infections/subject/year (EU) and 2.38. infections/subject/year (US). The rate of bronchopulmonary infections was higher in the EU study. No treatment-related serious AEs occurred; no subject discontinued because of treatment-related AEs. Self-administered Hizentra afforded sustained effective protection from infections and favorable tolerability during an extended treatment period of up to 3. years.",
keywords = "20{\%} SCIG, Hizentra, Primary immunodeficiency, Subcutaneous immunoglobulin",
author = "Stephen Jolles and Michael Borte and Robert Nelson and Mikhail Rojavin and Martin Bexon and Lawo, {John Philip} and Wasserman, {Richard L.}",
year = "2014",
month = "2",
doi = "10.1016/j.clim.2013.10.008",
language = "English (US)",
volume = "150",
pages = "161--169",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

AU - Jolles, Stephen

AU - Borte, Michael

AU - Nelson, Robert

AU - Rojavin, Mikhail

AU - Bexon, Martin

AU - Lawo, John Philip

AU - Wasserman, Richard L.

PY - 2014/2

Y1 - 2014/2

N2 - Hizentra® (20% subcutaneous immunoglobulin [SCIG]) was administered to subjects with primary immunodeficiency disease in two extension studies in the EU and US to assess long-term efficacy and tolerability. Subjects (aged 4-69. years) were treated for 148. weeks in the EU (N. = 40; 5405 infusions) and 87. weeks in the US (N. = 21; 1735 infusions). Weekly doses were 116.0. mg/kg (EU) and 193.2. mg/kg (US); IgG levels were 7.97. g/L (EU) and 11.98. g/L (US). Annualized rates of serious bacterial infections were 0.05. infections/subject/year (EU) and 0.06. infections/subject/year (US). Rates of any infection were 3.33. infections/subject/year (EU) and 2.38. infections/subject/year (US). The rate of bronchopulmonary infections was higher in the EU study. No treatment-related serious AEs occurred; no subject discontinued because of treatment-related AEs. Self-administered Hizentra afforded sustained effective protection from infections and favorable tolerability during an extended treatment period of up to 3. years.

AB - Hizentra® (20% subcutaneous immunoglobulin [SCIG]) was administered to subjects with primary immunodeficiency disease in two extension studies in the EU and US to assess long-term efficacy and tolerability. Subjects (aged 4-69. years) were treated for 148. weeks in the EU (N. = 40; 5405 infusions) and 87. weeks in the US (N. = 21; 1735 infusions). Weekly doses were 116.0. mg/kg (EU) and 193.2. mg/kg (US); IgG levels were 7.97. g/L (EU) and 11.98. g/L (US). Annualized rates of serious bacterial infections were 0.05. infections/subject/year (EU) and 0.06. infections/subject/year (US). Rates of any infection were 3.33. infections/subject/year (EU) and 2.38. infections/subject/year (US). The rate of bronchopulmonary infections was higher in the EU study. No treatment-related serious AEs occurred; no subject discontinued because of treatment-related AEs. Self-administered Hizentra afforded sustained effective protection from infections and favorable tolerability during an extended treatment period of up to 3. years.

KW - 20% SCIG

KW - Hizentra

KW - Primary immunodeficiency

KW - Subcutaneous immunoglobulin

UR - http://www.scopus.com/inward/record.url?scp=84891894977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891894977&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2013.10.008

DO - 10.1016/j.clim.2013.10.008

M3 - Article

VL - 150

SP - 161

EP - 169

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -